REG - ReNeuron Group plc - Director Share Purchase <Origin Href="QuoteRef">RQE.L</Origin>

ReNeuronAnnouncement

03/02/2016 10:10

RNS Number : 9378N
ReNeuron Group plc
03 February 2016
3 February 2016
AIM: RENE
ReNeuron Group plc 
Director share purchase
Guildford, UK, 3 February 2016:ReNeuron Group plc (AIM: RENE), a leading UK-based stem cell therapy company, was informed on 3 February 2016 that one of its Directors acquired ordinary shares of 1p each ("Ordinary Shares") as follows:




Interest after purchase
Director 
Date of transaction
Number of Ordinary Shares acquired 
Price
per share 
Number of Ordinary Shares
% of total
issued share capital
John Berriman
(Non-executive Chairman)
2 February 2016
318,476
3.14p
1,043,476
0.033%
The issued share capital of the Company is 3,159,256,868 1p ordinary shares.
Enquiries:
ReNeuron
+44 (0)20 3819 8400
Olav Helleb , Chief Executive Officer

Michael Hunt, Chief Financial Officer

Buchanan
+44 (0) 20 7466 5000
Mark Court, Sophie Cowles, Stephanie Watson



Cenkos Securities
+44 (0) 20 7397 8900
Stephen Keys, Dr Christopher Golden (NOMAD and Broker)

Russell Kerr (Sales)

About ReNeuron
ReNeuron is a leading, clinical-stage cell therapy development company. Based in the UK, its primary objective is the development of novel cell-based therapies targeting areas of significant unmet or poorly met medical need. 
ReNeuron has used its unique stem cell technologies to develop cell-based therapies for significant disease conditions where the cells can be readily administered "off-the-shelf" to any eligible patient without the need for additional immunosuppressive drug treatments. The Company has therapeutic candidates in clinical development for motor disability as a result of stroke, for critical limb ischaemia and for the blindness-causing disease, retinitis pigmentosa. 
ReNeuron is also advancing its proprietary exosome technology platform as a potential new nanomedicine targeting cancer and as a potential delivery system for gene therapy treatments.
ReNeuron's shares are traded on the London AIM market under the symbol RENE.L. Further information on ReNeuron and its products can be found at www.reneuron.com.
This announcement contains forward-looking statements with respect to the financial condition, results of operations and business achievements/performance of ReNeuron and certain of the plans and objectives of management of ReNeuron with respect thereto. These statements may generally, but not always, be identified by the use of words such as "should", "expects", "estimates", "believes" or similar expressions. This announcement also contains forward-looking statements attributed to certain third parties relating to their estimates regarding the growth of markets and demand for products. By their nature, forward-looking statements involve risk and uncertainty because they reflect ReNeuron's current expectations and assumptions as to future events and circumstances that may not prove accurate. A number of factors could cause ReNeuron's actual financial condition, results of operations and business achievements/performance to differ materially from the estimates made or implied in such forward-looking statements and, accordingly, reliance should not be placed on such statements.

This information is provided by RNS
The company news service from the London Stock Exchange
  END
RDSUORRRNVAURAR